Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119671) titled 'Efficacy and Safety of Camrelizumab plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma with Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study' on March 2.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Xiangya Hospital Central South University
Condition:
Hepatocellular Carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-02
Target Sample Size: Camrelizumab plus Rivoceranib and Local Therapy:32;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=...